Germany Pharmaceuticals Market

Germany Pharmaceuticals Market Size, Share, Growth Analysis, By Drug Class(Anti-cancer, Anti-diabetics), By Application(Oncology, Breast cancer), By Infectious Diseases(Cardiovascular Diseases, Central Nervous System Disorders), By Type(Branded, Generics) - Industry Forecast 2024-2031

Report ID: UCMIR35I2241 | Region: Regional | Published Date: Upcoming |
Pages: 165 | Tables: 55 | Figures: 60

Germany Pharmaceuticals Market Insights

Market Overview:

The pharmaceuticals market in Germany achieved a valuation of USD 41.4 billion in 2019, serving as a testament to its robust standing within the industry. Forecasts indicate a trajectory of continued growth, with a projected compound annual growth rate (CAGR) of 6.0% from 2020 to 2027. This positive trend is largely attributed to the nation's dynamic healthcare landscape and its commitment to innovative medical solutions. As Germany's pharmaceutical sector continues to evolve, the convergence of advancements, investments, and healthcare initiatives is expected to underpin its sustained expansion in the years ahead.

Germany Pharmaceuticals Market, Forecast & Y-O-Y Growth Rate, 2020 - 2028
ForecastGrowthRate
To get more reports on the above market click here to
GET FREE SAMPLE

This report is being written to illustrate the market opportunity by region and by segments, indicating opportunity areas for the vendors to tap upon. To estimate the opportunity, it was very important to understand the current market scenario and the way it will grow in future.

Production and consumption patterns are being carefully compared to forecast the market. Other factors considered to forecast the market are the growth of the adjacent market, revenue growth of the key market vendors, scenario-based analysis, and market segment growth.

The market size was determined by estimating the market through a top-down and bottom-up approach, which was further validated with industry interviews. Considering the nature of the market we derived the Pharmaceuticals by segment aggregation, the contribution of the Pharmaceuticals in Pharmaceuticals, Biotechnology & Life Sciences and vendor share.

To determine the growth of the market factors such as drivers, trends, restraints, and opportunities were identified, and the impact of these factors was analyzed to determine the market growth. To understand the market growth in detail, we have analyzed the year-on-year growth of the market. Also, historic growth rates were compared to determine growth patterns.

Segmentation Analysis:

The Germany Pharmaceuticals Market is segmented by Drug Class, Application, Infectious Diseases, Type. We are analyzing the market of these segments to identify which segment is the largest now and in the future, which segment has the highest growth rate, and the segment which offers the opportunity in the future.

Germany Pharmaceuticals Market Basis Point Share Analysis, 2021 Vs. 2028
BasisPointShareAnalysis
To get detailed analysis on all segments
BUY NOW
  • Based on Drug Class the market is segmented as, Anti-cancer, Anti-diabetics, Anti-rheumatics, Vaccines, Anti-viral, Immunosuppressant, Bronchodilators, Dermatological, Anti-hypertensive, Others
  • Based on Application the market is segmented as, Oncology, Breast cancer, Lung cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Others
  • Based on Infectious Diseases the market is segmented as, Cardiovascular Diseases, Central Nervous System Disorders, Immunological Disorders, Metabolic Disorders, Gastrointestinal Disorders, Respiratory Diseases, Ophthalmology, Dermatology Disorders, Others
  • Based on Type the market is segmented as, Branded, Generics, Formulation, Solid formulation, Tablets, Capsules, Others, Liquid & semi-liquid formulation, Oral, Topical, Sublingual and buccal, Rectal, Parenteral, KEY MARKET PLAYERS, Boehringer Ingelheim International GmbH, Bayer AG, Merck & Co., Inc., Fresenius Kabi AG, STADA Arzneimittel AG, Pfizer Inc., Abbott, Abbvie Inc., Teva Pharmaceutical Industries Ltd.

Regional Analysis:

Germany Pharmaceuticals Market is being analyzed by North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA) regions. Key countries including the U.S., Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Brazil, GCC Countries, and South Africa among others were analyzed considering various micro and macro trends.

Germany Pharmaceuticals Market Attractiveness Analysis, By Region 2020-2028
AttractivenessAnalysis
To know more about the market opportunities by region and country, click here to
REQUEST FREE CUSTOMIZATION

Germany Pharmaceuticals Market : Risk Analysis

SkyQuest's expert analysts have conducted a risk analysis to understand the impact of external extremities on Germany Pharmaceuticals Market. We analyzed how geopolitical influence, natural disasters, climate change, legal scenario, economic impact, trade & economic policies, social & ethnic concerns, and demographic changes might affect Germany Pharmaceuticals Market's supply chain, distribution, and total revenue growth.

Competitive landscaping:

To understand the competitive landscape, we are analyzing key Germany Pharmaceuticals Market vendors in the market. To understand the competitive rivalry, we are comparing the revenue, expenses, resources, product portfolio, region coverage, market share, key initiatives, product launches, and any news related to the Germany Pharmaceuticals Market.

To validate our hypothesis and validate our findings on the market ecosystem, we are also conducting a detailed porter's five forces analysis. Competitive Rivalry, Supplier Power, Buyer Power, Threat of Substitution, and Threat of New Entry each force is analyzed by various parameters governing those forces.

Key Players Covered in the Report:

  • rview
  • The Germany pharmaceuticals market size was valued at USD 41.4 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 6.0% from 2020 to 2027. Increasing patent applications that are focused on the development of novel drug delivery systems, new drugs, and formulations is anticipated to boost the market for pharmaceuticals. According to the European Patent Office (EPO) Patent Index 2019, the number of patent applications increased by 4.4% in 2018 in the pharmaceutical field. Therefore, growth in patent applications is estimated to accelerate innovations in the pharmaceutical industry. Furthermore, the growing export of pharmaceuticals from the Federal Republic of Germany to various countries is anticipated to boost the growth of the market for pharmaceuticals. For instance, according to the German Pharmaceutical Industry Association (BPI), in 2018, pharmaceuticals worth USD 98.6 billion were exported from Germany.
  • This corresponds to an increase of 10.3% over the previous year. Furthermore, the U.S., Netherlands, and Switzerland are the top three main customers for pharmaceuticals from Germany. Favorable reimbursement scenario and pricing for pharmaceuticals companies &customers are expected to fuel the growth of the market for pharmaceuticals. For instance, in Germany, 90% of the population is covered from Statutory Health Insurance (SHI) and the remaining 10.0% is covered by special schemes and private insurance.
  • The presence of strong pipeline drugs in Phase III clinical trials are expected to be commercialized over the forecast period, thereby, driving the growth of the market for pharmaceuticals. For instance, Boehringer Ingelheim International GmbH’s R & D pipeline consists of two candidates namely Empagliflozin and Nintedanib under phase III clinical trial for cardiovascular diseases and respiratory diseases.
  • Drug Class Insights
  • The anti-cancer segment accounted for the largest revenue share of 15.6% in 2019 due to the increasing prevalence of cancer and the commercialization of novel therapies to treat various types of cancers. For instance, according to GLOBOCAN 2018, there were 71, 888 new cases of breast cancer, followed by lung cancer with 66,749 new cases, and 62,641 new prostate cancer cases.
  • Key players are developing new drugs to combat the rising cases of cancer, thereby, accelerating the market for pharmaceuticals. For instance, in March 2020, Nubeqa (darolutamide) received marketing authorization from the European Commission. The compound is an oral Androgen Receptor inhibitor (ARi) developed by Bayer in collaboration with Orion Corporation to treat non-metastatic castration-resistant prostate cancer (nmCRPC).
  • Increasing research initiatives to develop novel drugs for treatment against different viruses is expected to boost the Germany pharmaceuticals market. For instance, in March 2020, a study was published by a group of scientists from Germany that demonstrated the use of Camostat Mesylate against COVID-19 caused by SARS–CoV-2 coronavirus. The study found that SARS-CoV-2 requires a cellular protein TMPRSS2 in the human body to enter host cells. Therefore, the Japanese FDA approved the drug Camostat Mesylate which is active against coronavirus and has the potential to block TMPRSS2.
  • Type Insights
  • The branded drugs segment dominated the market for pharmaceuticals and accounted for the largest revenue share in 2019. Increasing R&D efforts, increased adoption of novel therapies, and strategic collaborations driving wide-scale penetration of drugs are few contributing factors for the growth of this segment.
  • However, the emergence of biosimilars has heralded a significant shift in the cancer treatment landscape in Germany. The expiration of patent exclusivities and rising need for cost-effective drugs are fueling the penetration of biosimilars and generic drugs into the market for pharmaceuticals. Therefore, generic drugs are estimated to be the fastest-growing segment during the forecast period. Furthermore, key players are acquiring a generic product portfolio to acquire a higher market share in the generic market over the forecast period. For instance, in February 2020, STADA AG acquired GlaxoSmithKline plc’s consumer healthcare brands such as Venoruton, Tavegyl allergy brand, Mebucaine sore throat range, Cetebe vitamin C supplements, and Coldrex cold remedy.
  • Formulations Insights
  • The solid formulation segment is expected to witness a significant CAGR owing to its cost-effectiveness and several other benefits associated with its administration. In addition, local players undergoing strategic initiatives such as collaboration and licensing to expand their presence in new regions is anticipated to drive the market for pharmaceuticals in Germany.
  • For instance, in December 2019, Bausch Health Companies Inc. & Bausch + Lomb acquired an exclusive license to commercialize and develop Novaliq GmbH’s investigational candidate NOV03 (perfluorohexyloctane). NOV03 is a solution for the treatment of DED associated with Meibomian gland dysfunction (MGD)
  • Application Insights
  • Oncology accounted for the largest revenue share of 15.5% in 2019 owing to increasing strategic initiatives such as collaboration, partnership, & others to develop & strengthen their portfolio. For instance, in September 2019, Boehringer Ingelheim International GmbH and Lupin Ltd entered into a partnership to license, develop, and commercialize Lupin’s MEK inhibitor compound (LNP3794) for the treatment of cancers. Under the agreement, Boehringer Ingelheim will develop innovative KRAS inhibitors in combination with Lupin’s lead MEK inhibitor compound for gastrointestinal and lung cancers.
  • Furthermore, companies have developed new drugs to increase the availability of prescription drugs which is anticipated to accelerate the market for pharmaceuticals in Germany. For instance, in March 2019, Rubraca was made available in Germany as a prescription drug for ovarian cancer, developed by Clovis Oncology, Inc.
  • Key Companies & Market Share Insights
  • Key players are focusing on the development and approval of new vaccines for infectious diseases in order to maintain a significant share in the market for pharmaceuticals in Germany. For instance, in November 2019, Merck Sharp and Dohme Corporation’s ERVEBO vaccine was approved by the EU Commission against the Zaire Ebola virus for people of age 18 years and above.
  • KEY MARKET SEGMENTS
  • By Drug Class
  • Anti-cancer
  • Anti-diabetics
  • Anti-rheumatics
  • Vaccines
  • Anti-viral
  • Immunosuppressant
  • Bronchodilators
  • Dermatological
  • Anti-hypertensive
  • Others
  • By Application
  • Oncology
  • Breast cancer
  • Lung cancer
  • Colorectal cancer
  • Ovarian cancer
  • Prostate cancer
  • Others
  • By Infectious Diseases
  • Cardiovascular Diseases
  • Central Nervous System Disorders
  • Immunological Disorders
  • Metabolic Disorders
  • Gastrointestinal Disorders
  • Respiratory Diseases
  • Ophthalmology
  • Dermatology Disorders
  • Others
  • By Type
  • Branded
  • Generics
  • Formulation
  • Solid formulation
  • Tablets
  • Capsules
  • Others
  • Liquid & semi-liquid formulation
  • Oral
  • Topical
  • Sublingual and buccal
  • Rectal
  • Parenteral
  • KEY MARKET PLAYERS
  • Boehringer Ingelheim International GmbH
  • Bayer AG
  • Merck & Co., Inc.
  • Fresenius Kabi AG
  • STADA Arzneimittel AG
  • Pfizer Inc.
  • Abbott
  • Abbvie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG"

SkyQuest's Expertise:

The Germany Pharmaceuticals Market is being analyzed by SkyQuest's analysts with the help of 20+ scheduled Primary interviews from both the demand and supply sides. We have already invested more than 250 hours on this report and are still refining our date to provide authenticated data to your readers and clients. Exhaustive primary and secondary research is conducted to collect information on the market, peer market, and parent market.

Our cross-industry experts and revenue-impact consultants at SkyQuest enable our clients to convert market intelligence into actionable, quantifiable results through personalized engagement.

Scope Of Report

Report Attribute Details
The base year for estimation 2021
Historical data 2016 – 2022
Forecast period 2022 – 2028
Report coverage Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis
Segments covered
  • By Drug Class - Anti-cancer, Anti-diabetics, Anti-rheumatics, Vaccines, Anti-viral, Immunosuppressant, Bronchodilators, Dermatological, Anti-hypertensive, Others
  • By Application - Oncology, Breast cancer, Lung cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Others
  • By Infectious Diseases - Cardiovascular Diseases, Central Nervous System Disorders, Immunological Disorders, Metabolic Disorders, Gastrointestinal Disorders, Respiratory Diseases, Ophthalmology, Dermatology Disorders, Others
  • By Type - Branded, Generics, Formulation, Solid formulation, Tablets, Capsules, Others, Liquid & semi-liquid formulation, Oral, Topical, Sublingual and buccal, Rectal, Parenteral, KEY MARKET PLAYERS, Boehringer Ingelheim International GmbH, Bayer AG, Merck & Co., Inc., Fresenius Kabi AG, STADA Arzneimittel AG, Pfizer Inc., Abbott, Abbvie Inc., Teva Pharmaceutical Industries Ltd.
Regional scope North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA)
Country scope U.S., Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Brazil, GCC Countries, South Africa
Key companies profiled
  • rview
  • The Germany pharmaceuticals market size was valued at USD 41.4 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 6.0% from 2020 to 2027. Increasing patent applications that are focused on the development of novel drug delivery systems, new drugs, and formulations is anticipated to boost the market for pharmaceuticals. According to the European Patent Office (EPO) Patent Index 2019, the number of patent applications increased by 4.4% in 2018 in the pharmaceutical field. Therefore, growth in patent applications is estimated to accelerate innovations in the pharmaceutical industry. Furthermore, the growing export of pharmaceuticals from the Federal Republic of Germany to various countries is anticipated to boost the growth of the market for pharmaceuticals. For instance, according to the German Pharmaceutical Industry Association (BPI), in 2018, pharmaceuticals worth USD 98.6 billion were exported from Germany.
  • This corresponds to an increase of 10.3% over the previous year. Furthermore, the U.S., Netherlands, and Switzerland are the top three main customers for pharmaceuticals from Germany. Favorable reimbursement scenario and pricing for pharmaceuticals companies &customers are expected to fuel the growth of the market for pharmaceuticals. For instance, in Germany, 90% of the population is covered from Statutory Health Insurance (SHI) and the remaining 10.0% is covered by special schemes and private insurance.
  • The presence of strong pipeline drugs in Phase III clinical trials are expected to be commercialized over the forecast period, thereby, driving the growth of the market for pharmaceuticals. For instance, Boehringer Ingelheim International GmbH’s R & D pipeline consists of two candidates namely Empagliflozin and Nintedanib under phase III clinical trial for cardiovascular diseases and respiratory diseases.
  • Drug Class Insights
  • The anti-cancer segment accounted for the largest revenue share of 15.6% in 2019 due to the increasing prevalence of cancer and the commercialization of novel therapies to treat various types of cancers. For instance, according to GLOBOCAN 2018, there were 71, 888 new cases of breast cancer, followed by lung cancer with 66,749 new cases, and 62,641 new prostate cancer cases.
  • Key players are developing new drugs to combat the rising cases of cancer, thereby, accelerating the market for pharmaceuticals. For instance, in March 2020, Nubeqa (darolutamide) received marketing authorization from the European Commission. The compound is an oral Androgen Receptor inhibitor (ARi) developed by Bayer in collaboration with Orion Corporation to treat non-metastatic castration-resistant prostate cancer (nmCRPC).
  • Increasing research initiatives to develop novel drugs for treatment against different viruses is expected to boost the Germany pharmaceuticals market. For instance, in March 2020, a study was published by a group of scientists from Germany that demonstrated the use of Camostat Mesylate against COVID-19 caused by SARS–CoV-2 coronavirus. The study found that SARS-CoV-2 requires a cellular protein TMPRSS2 in the human body to enter host cells. Therefore, the Japanese FDA approved the drug Camostat Mesylate which is active against coronavirus and has the potential to block TMPRSS2.
  • Type Insights
  • The branded drugs segment dominated the market for pharmaceuticals and accounted for the largest revenue share in 2019. Increasing R&D efforts, increased adoption of novel therapies, and strategic collaborations driving wide-scale penetration of drugs are few contributing factors for the growth of this segment.
  • However, the emergence of biosimilars has heralded a significant shift in the cancer treatment landscape in Germany. The expiration of patent exclusivities and rising need for cost-effective drugs are fueling the penetration of biosimilars and generic drugs into the market for pharmaceuticals. Therefore, generic drugs are estimated to be the fastest-growing segment during the forecast period. Furthermore, key players are acquiring a generic product portfolio to acquire a higher market share in the generic market over the forecast period. For instance, in February 2020, STADA AG acquired GlaxoSmithKline plc’s consumer healthcare brands such as Venoruton, Tavegyl allergy brand, Mebucaine sore throat range, Cetebe vitamin C supplements, and Coldrex cold remedy.
  • Formulations Insights
  • The solid formulation segment is expected to witness a significant CAGR owing to its cost-effectiveness and several other benefits associated with its administration. In addition, local players undergoing strategic initiatives such as collaboration and licensing to expand their presence in new regions is anticipated to drive the market for pharmaceuticals in Germany.
  • For instance, in December 2019, Bausch Health Companies Inc. & Bausch + Lomb acquired an exclusive license to commercialize and develop Novaliq GmbH’s investigational candidate NOV03 (perfluorohexyloctane). NOV03 is a solution for the treatment of DED associated with Meibomian gland dysfunction (MGD)
  • Application Insights
  • Oncology accounted for the largest revenue share of 15.5% in 2019 owing to increasing strategic initiatives such as collaboration, partnership, & others to develop & strengthen their portfolio. For instance, in September 2019, Boehringer Ingelheim International GmbH and Lupin Ltd entered into a partnership to license, develop, and commercialize Lupin’s MEK inhibitor compound (LNP3794) for the treatment of cancers. Under the agreement, Boehringer Ingelheim will develop innovative KRAS inhibitors in combination with Lupin’s lead MEK inhibitor compound for gastrointestinal and lung cancers.
  • Furthermore, companies have developed new drugs to increase the availability of prescription drugs which is anticipated to accelerate the market for pharmaceuticals in Germany. For instance, in March 2019, Rubraca was made available in Germany as a prescription drug for ovarian cancer, developed by Clovis Oncology, Inc.
  • Key Companies & Market Share Insights
  • Key players are focusing on the development and approval of new vaccines for infectious diseases in order to maintain a significant share in the market for pharmaceuticals in Germany. For instance, in November 2019, Merck Sharp and Dohme Corporation’s ERVEBO vaccine was approved by the EU Commission against the Zaire Ebola virus for people of age 18 years and above.
  • KEY MARKET SEGMENTS
  • By Drug Class
  • Anti-cancer
  • Anti-diabetics
  • Anti-rheumatics
  • Vaccines
  • Anti-viral
  • Immunosuppressant
  • Bronchodilators
  • Dermatological
  • Anti-hypertensive
  • Others
  • By Application
  • Oncology
  • Breast cancer
  • Lung cancer
  • Colorectal cancer
  • Ovarian cancer
  • Prostate cancer
  • Others
  • By Infectious Diseases
  • Cardiovascular Diseases
  • Central Nervous System Disorders
  • Immunological Disorders
  • Metabolic Disorders
  • Gastrointestinal Disorders
  • Respiratory Diseases
  • Ophthalmology
  • Dermatology Disorders
  • Others
  • By Type
  • Branded
  • Generics
  • Formulation
  • Solid formulation
  • Tablets
  • Capsules
  • Others
  • Liquid & semi-liquid formulation
  • Oral
  • Topical
  • Sublingual and buccal
  • Rectal
  • Parenteral
  • KEY MARKET PLAYERS
  • Boehringer Ingelheim International GmbH
  • Bayer AG
  • Merck & Co., Inc.
  • Fresenius Kabi AG
  • STADA Arzneimittel AG
  • Pfizer Inc.
  • Abbott
  • Abbvie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG"
Customization scope Free report customization (15% Free customization) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options Reap the benefits of customized purchase options to fit your specific research requirements.

Objectives of the Study

  • To forecast the market size, in terms of value, for various segments with respect to five main regions, namely, North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA)
  • To provide detailed information regarding the major factors influencing the growth of the Market (drivers, restraints, opportunities, and challenges)
  • To strategically analyze the micro markets with respect to the individual growth trends, future prospects, and contribution to the total market
  • To provide a detailed overview of the value chain and analyze market trends with the Porter's five forces analysis
  • To analyze the opportunities in the market for various stakeholders by identifying the high-growth Segments
  • To identify the key players and comprehensively analyze their market position in terms of ranking and core competencies, along with detailing the competitive landscape for the market leaders
  • To analyze competitive development such as joint ventures, mergers and acquisitions, new product launches and development, and research and development in the market

What does this Report Deliver?

  • Market Estimation for 20+ Countries
  • Historical data coverage: 2016 to 2022
  • Growth projections: 2022 to 2028
  • SkyQuest's premium market insights: Innovation matrix, IP analysis, Production Analysis, Value chain analysis, Technological trends, and Trade analysis
  • Customization on Segments, Regions, and Company Profiles
  • 100+ tables, 150+ Figures, 10+ matrix
  • Global and Country Market Trends
  • Comprehensive Mapping of Industry Parameters
  • Attractive Investment Proposition
  • Competitive Strategies Adopted by Leading Market Participants
  • Market drivers, restraints, opportunities, and its impact on the market
  • Regulatory scenario, regional dynamics, and insights of leading countries in each region
  • Segment trends analysis, opportunity, and growth
  • Opportunity analysis by region and country
  • Porter's five force analysis to know the market's condition
  • Pricing analysis
  • Parent market analysis
  • Product portfolio benchmarking

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Germany Pharmaceuticals Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Germany Pharmaceuticals Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)
  • rview
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The Germany pharmaceuticals market size was valued at USD 41.4 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 6.0% from 2020 to 2027. Increasing patent applications that are focused on the development of novel drug delivery systems, new drugs, and formulations is anticipated to boost the market for pharmaceuticals. According to the European Patent Office (EPO) Patent Index 2019, the number of patent applications increased by 4.4% in 2018 in the pharmaceutical field. Therefore, growth in patent applications is estimated to accelerate innovations in the pharmaceutical industry. Furthermore, the growing export of pharmaceuticals from the Federal Republic of Germany to various countries is anticipated to boost the growth of the market for pharmaceuticals. For instance, according to the German Pharmaceutical Industry Association (BPI), in 2018, pharmaceuticals worth USD 98.6 billion were exported from Germany.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • This corresponds to an increase of 10.3% over the previous year. Furthermore, the U.S., Netherlands, and Switzerland are the top three main customers for pharmaceuticals from Germany. Favorable reimbursement scenario and pricing for pharmaceuticals companies &customers are expected to fuel the growth of the market for pharmaceuticals. For instance, in Germany, 90% of the population is covered from Statutory Health Insurance (SHI) and the remaining 10.0% is covered by special schemes and private insurance.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The presence of strong pipeline drugs in Phase III clinical trials are expected to be commercialized over the forecast period, thereby, driving the growth of the market for pharmaceuticals. For instance, Boehringer Ingelheim International GmbH’s R & D pipeline consists of two candidates namely Empagliflozin and Nintedanib under phase III clinical trial for cardiovascular diseases and respiratory diseases.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Drug Class Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The anti-cancer segment accounted for the largest revenue share of 15.6% in 2019 due to the increasing prevalence of cancer and the commercialization of novel therapies to treat various types of cancers. For instance, according to GLOBOCAN 2018, there were 71, 888 new cases of breast cancer, followed by lung cancer with 66,749 new cases, and 62,641 new prostate cancer cases.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Key players are developing new drugs to combat the rising cases of cancer, thereby, accelerating the market for pharmaceuticals. For instance, in March 2020, Nubeqa (darolutamide) received marketing authorization from the European Commission. The compound is an oral Androgen Receptor inhibitor (ARi) developed by Bayer in collaboration with Orion Corporation to treat non-metastatic castration-resistant prostate cancer (nmCRPC).
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Increasing research initiatives to develop novel drugs for treatment against different viruses is expected to boost the Germany pharmaceuticals market. For instance, in March 2020, a study was published by a group of scientists from Germany that demonstrated the use of Camostat Mesylate against COVID-19 caused by SARS–CoV-2 coronavirus. The study found that SARS-CoV-2 requires a cellular protein TMPRSS2 in the human body to enter host cells. Therefore, the Japanese FDA approved the drug Camostat Mesylate which is active against coronavirus and has the potential to block TMPRSS2.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Type Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The branded drugs segment dominated the market for pharmaceuticals and accounted for the largest revenue share in 2019. Increasing R&D efforts, increased adoption of novel therapies, and strategic collaborations driving wide-scale penetration of drugs are few contributing factors for the growth of this segment.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • However, the emergence of biosimilars has heralded a significant shift in the cancer treatment landscape in Germany. The expiration of patent exclusivities and rising need for cost-effective drugs are fueling the penetration of biosimilars and generic drugs into the market for pharmaceuticals. Therefore, generic drugs are estimated to be the fastest-growing segment during the forecast period. Furthermore, key players are acquiring a generic product portfolio to acquire a higher market share in the generic market over the forecast period. For instance, in February 2020, STADA AG acquired GlaxoSmithKline plc’s consumer healthcare brands such as Venoruton, Tavegyl allergy brand, Mebucaine sore throat range, Cetebe vitamin C supplements, and Coldrex cold remedy.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Formulations Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The solid formulation segment is expected to witness a significant CAGR owing to its cost-effectiveness and several other benefits associated with its administration. In addition, local players undergoing strategic initiatives such as collaboration and licensing to expand their presence in new regions is anticipated to drive the market for pharmaceuticals in Germany.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • For instance, in December 2019, Bausch Health Companies Inc. & Bausch + Lomb acquired an exclusive license to commercialize and develop Novaliq GmbH’s investigational candidate NOV03 (perfluorohexyloctane). NOV03 is a solution for the treatment of DED associated with Meibomian gland dysfunction (MGD)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Application Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Oncology accounted for the largest revenue share of 15.5% in 2019 owing to increasing strategic initiatives such as collaboration, partnership, & others to develop & strengthen their portfolio. For instance, in September 2019, Boehringer Ingelheim International GmbH and Lupin Ltd entered into a partnership to license, develop, and commercialize Lupin’s MEK inhibitor compound (LNP3794) for the treatment of cancers. Under the agreement, Boehringer Ingelheim will develop innovative KRAS inhibitors in combination with Lupin’s lead MEK inhibitor compound for gastrointestinal and lung cancers.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Furthermore, companies have developed new drugs to increase the availability of prescription drugs which is anticipated to accelerate the market for pharmaceuticals in Germany. For instance, in March 2019, Rubraca was made available in Germany as a prescription drug for ovarian cancer, developed by Clovis Oncology, Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Key Companies & Market Share Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Key players are focusing on the development and approval of new vaccines for infectious diseases in order to maintain a significant share in the market for pharmaceuticals in Germany. For instance, in November 2019, Merck Sharp and Dohme Corporation’s ERVEBO vaccine was approved by the EU Commission against the Zaire Ebola virus for people of age 18 years and above.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • KEY MARKET SEGMENTS
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Drug Class
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Anti-cancer
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Anti-diabetics
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Anti-rheumatics
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Vaccines
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Anti-viral
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Immunosuppressant
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Bronchodilators
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Dermatological
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Anti-hypertensive
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Others
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Application
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Oncology
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Breast cancer
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Lung cancer
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Colorectal cancer
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Ovarian cancer
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Prostate cancer
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Others
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Infectious Diseases
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Cardiovascular Diseases
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Central Nervous System Disorders
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Immunological Disorders
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Metabolic Disorders
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Gastrointestinal Disorders
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Respiratory Diseases
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Ophthalmology
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Dermatology Disorders
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Others
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Type
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Branded
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Generics
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Formulation
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Solid formulation
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Tablets
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Capsules
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Others
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Liquid & semi-liquid formulation
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Oral
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Topical
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Sublingual and buccal
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Rectal
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Parenteral
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • KEY MARKET PLAYERS
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Boehringer Ingelheim International GmbH
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Bayer AG
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Merck & Co., Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Fresenius Kabi AG
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • STADA Arzneimittel AG
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Pfizer Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Abbott
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Abbvie Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Teva Pharmaceutical Industries Ltd.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Novartis AG"
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments

Methodology

For the Germany Pharmaceuticals Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Germany Pharmaceuticals Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Germany Pharmaceuticals Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Germany Pharmaceuticals Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

The global market for Germany Pharmaceuticals was estimated to be valued at US$ XX Mn in 2021.

The global Germany Pharmaceuticals Market is estimated to grow at a CAGR of XX% by 2028.

The global Germany Pharmaceuticals Market is segmented on the basis of Drug Class, Application, Infectious Diseases, Type.

Based on region, the global Germany Pharmaceuticals Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

The key players operating in the global Germany Pharmaceuticals Market are rview , The Germany pharmaceuticals market size was valued at USD 41.4 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 6.0% from 2020 to 2027. Increasing patent applications that are focused on the development of novel drug delivery systems, new drugs, and formulations is anticipated to boost the market for pharmaceuticals. According to the European Patent Office (EPO) Patent Index 2019, the number of patent applications increased by 4.4% in 2018 in the pharmaceutical field. Therefore, growth in patent applications is estimated to accelerate innovations in the pharmaceutical industry. Furthermore, the growing export of pharmaceuticals from the Federal Republic of Germany to various countries is anticipated to boost the growth of the market for pharmaceuticals. For instance, according to the German Pharmaceutical Industry Association (BPI), in 2018, pharmaceuticals worth USD 98.6 billion were exported from Germany. , This corresponds to an increase of 10.3% over the previous year. Furthermore, the U.S., Netherlands, and Switzerland are the top three main customers for pharmaceuticals from Germany. Favorable reimbursement scenario and pricing for pharmaceuticals companies &customers are expected to fuel the growth of the market for pharmaceuticals. For instance, in Germany, 90% of the population is covered from Statutory Health Insurance (SHI) and the remaining 10.0% is covered by special schemes and private insurance. , The presence of strong pipeline drugs in Phase III clinical trials are expected to be commercialized over the forecast period, thereby, driving the growth of the market for pharmaceuticals. For instance, Boehringer Ingelheim International GmbH’s R & D pipeline consists of two candidates namely Empagliflozin and Nintedanib under phase III clinical trial for cardiovascular diseases and respiratory diseases. , Drug Class Insights , The anti-cancer segment accounted for the largest revenue share of 15.6% in 2019 due to the increasing prevalence of cancer and the commercialization of novel therapies to treat various types of cancers. For instance, according to GLOBOCAN 2018, there were 71, 888 new cases of breast cancer, followed by lung cancer with 66,749 new cases, and 62,641 new prostate cancer cases. , Key players are developing new drugs to combat the rising cases of cancer, thereby, accelerating the market for pharmaceuticals. For instance, in March 2020, Nubeqa (darolutamide) received marketing authorization from the European Commission. The compound is an oral Androgen Receptor inhibitor (ARi) developed by Bayer in collaboration with Orion Corporation to treat non-metastatic castration-resistant prostate cancer (nmCRPC). , Increasing research initiatives to develop novel drugs for treatment against different viruses is expected to boost the Germany pharmaceuticals market. For instance, in March 2020, a study was published by a group of scientists from Germany that demonstrated the use of Camostat Mesylate against COVID-19 caused by SARS–CoV-2 coronavirus. The study found that SARS-CoV-2 requires a cellular protein TMPRSS2 in the human body to enter host cells. Therefore, the Japanese FDA approved the drug Camostat Mesylate which is active against coronavirus and has the potential to block TMPRSS2. , Type Insights , The branded drugs segment dominated the market for pharmaceuticals and accounted for the largest revenue share in 2019. Increasing R&D efforts, increased adoption of novel therapies, and strategic collaborations driving wide-scale penetration of drugs are few contributing factors for the growth of this segment. , However, the emergence of biosimilars has heralded a significant shift in the cancer treatment landscape in Germany. The expiration of patent exclusivities and rising need for cost-effective drugs are fueling the penetration of biosimilars and generic drugs into the market for pharmaceuticals. Therefore, generic drugs are estimated to be the fastest-growing segment during the forecast period. Furthermore, key players are acquiring a generic product portfolio to acquire a higher market share in the generic market over the forecast period. For instance, in February 2020, STADA AG acquired GlaxoSmithKline plc’s consumer healthcare brands such as Venoruton, Tavegyl allergy brand, Mebucaine sore throat range, Cetebe vitamin C supplements, and Coldrex cold remedy. , Formulations Insights , The solid formulation segment is expected to witness a significant CAGR owing to its cost-effectiveness and several other benefits associated with its administration. In addition, local players undergoing strategic initiatives such as collaboration and licensing to expand their presence in new regions is anticipated to drive the market for pharmaceuticals in Germany. , For instance, in December 2019, Bausch Health Companies Inc. & Bausch + Lomb acquired an exclusive license to commercialize and develop Novaliq GmbH’s investigational candidate NOV03 (perfluorohexyloctane). NOV03 is a solution for the treatment of DED associated with Meibomian gland dysfunction (MGD) , Application Insights , Oncology accounted for the largest revenue share of 15.5% in 2019 owing to increasing strategic initiatives such as collaboration, partnership, & others to develop & strengthen their portfolio. For instance, in September 2019, Boehringer Ingelheim International GmbH and Lupin Ltd entered into a partnership to license, develop, and commercialize Lupin’s MEK inhibitor compound (LNP3794) for the treatment of cancers. Under the agreement, Boehringer Ingelheim will develop innovative KRAS inhibitors in combination with Lupin’s lead MEK inhibitor compound for gastrointestinal and lung cancers. , Furthermore, companies have developed new drugs to increase the availability of prescription drugs which is anticipated to accelerate the market for pharmaceuticals in Germany. For instance, in March 2019, Rubraca was made available in Germany as a prescription drug for ovarian cancer, developed by Clovis Oncology, Inc. , Key Companies & Market Share Insights , Key players are focusing on the development and approval of new vaccines for infectious diseases in order to maintain a significant share in the market for pharmaceuticals in Germany. For instance, in November 2019, Merck Sharp and Dohme Corporation’s ERVEBO vaccine was approved by the EU Commission against the Zaire Ebola virus for people of age 18 years and above. , KEY MARKET SEGMENTS, By Drug Class, Anti-cancer , Anti-diabetics , Anti-rheumatics , Vaccines , Anti-viral , Immunosuppressant , Bronchodilators , Dermatological , Anti-hypertensive , Others , By Application, Oncology , Breast cancer , Lung cancer , Colorectal cancer , Ovarian cancer , Prostate cancer , Others , By Infectious Diseases , Cardiovascular Diseases , Central Nervous System Disorders , Immunological Disorders , Metabolic Disorders , Gastrointestinal Disorders , Respiratory Diseases , Ophthalmology , Dermatology Disorders , Others , By Type, Branded , Generics , Formulation, Solid formulation , Tablets , Capsules , Others , Liquid & semi-liquid formulation , Oral , Topical , Sublingual and buccal , Rectal , Parenteral , KEY MARKET PLAYERS, Boehringer Ingelheim International GmbH , Bayer AG , Merck & Co., Inc. , Fresenius Kabi AG , STADA Arzneimittel AG , Pfizer Inc. , Abbott , Abbvie Inc. , Teva Pharmaceutical Industries Ltd. , Novartis AG".

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Germany Pharmaceuticals Market

Report ID: UCMIG35I2226 | Region: Global | Published Date: Upcoming | Pages: 165 | Tables: 55 | Figures: 60

Hybrid Power System Market
Buy Now GET FREE SAMPLE
Germany Pharmaceuticals Market

Report ID: SQMIG35I2201 | Region: Global | Published Date: Upcoming | Pages: 219 | Tables: 55 | Figures: 60

Global Eye Health Supplements Market
Buy Now GET FREE SAMPLE
Germany Pharmaceuticals Market

Report ID: UCMIG35I2192 | Region: Global | Published Date: Upcoming | Pages: 165 | Tables: 55 | Figures: 60

Glycomics Market
Buy Now GET FREE SAMPLE
Germany Pharmaceuticals Market

Report ID: SQMIG35I2117 | Region: Global | Published Date: Upcoming | Pages: 219 | Tables: 55 | Figures: 60

Global Zoonotic Disease Treatment Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Germany Pharmaceuticals Market

Product ID: UCMIR35I2241

$5,300
BUY NOW GET FREE SAMPLE